Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James F Sampson

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
European Journal of Immunology|April 7, 2011
Th17 differentiation is the default program for DPP2-deficient T-cell differentiationDeanna A Mele, James F Sampson, Brigitte T Huber
Journal of Immunology (Baltimore, Md. : 1950)|December 16, 2014
IL-17A-mediated protection against Acanthamoeba keratitisAmol Suryawanshi, Zhiyi Cao, James F Sampson, et al.
Immunology and Cell Biology|February 10, 2016
Galectin-8 promotes regulatory T-cell differentiation by modulating IL-2 and TGFβ signalingJames F Sampson, Amol Suryawanshi, Wei-Sheng Chen, et al.
Immunology and Cell Biology|August 19, 2015
Galectin-8 promotes regulatory T-cell differentiation by modulating IL-2 and TGFβ signalingJames F Sampson, Amol Suryawanshi, Wei-Sheng Chen, et al.
Experimental Eye Research|June 20, 2018
Collagen VII deficient mice show morphologic and histologic corneal changes that phenotypically mimic human dystrophic epidermolysis bullosa of the eyeVicki M Chen, Rajani Shelke, Alexander Nyström, et al.
Plos One|July 1, 2015
Galectin-8 Ameliorates Murine Autoimmune Ocular Pathology and Promotes a Regulatory T Cell ResponseJames F Sampson, Eiichi Hasegawa, Lama Mulki, et al.
Plos One|May 2, 2025
CD38-targeted attenuated interferon alpha immunocytokine activates both innate and adaptive immune cells to drive anti-tumor activityJames F Sampson, Hong Zhang, Dongmei Zhang, et al.
Molecular Cancer Therapeutics|October 11, 2019
Synergy between EphA2-ILs-DTXp, a Novel EphA2-Targeted Nanoliposomal Taxane, and PD-1 Inhibitors in Preclinical Tumor ModelsWalid S Kamoun, Anne-Sophie Dugast, James J Suchy, et al.
Science Translational Medicine|October 4, 2019
Antibody-mediated targeting of TNFR2 activates CD8<sup>+</sup> T cells in mice and promotes antitumor immunityEric M Tam, Ross B Fulton, James F Sampson, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
European Journal of Immunology|April 7, 2011
Th17 differentiation is the default program for DPP2-deficient T-cell differentiationDeanna A Mele, James F Sampson, Brigitte T Huber
Journal of Immunology (Baltimore, Md. : 1950)|December 16, 2014
IL-17A-mediated protection against Acanthamoeba keratitisAmol Suryawanshi, Zhiyi Cao, James F Sampson, et al.
Immunology and Cell Biology|February 10, 2016
Galectin-8 promotes regulatory T-cell differentiation by modulating IL-2 and TGFβ signalingJames F Sampson, Amol Suryawanshi, Wei-Sheng Chen, et al.
Immunology and Cell Biology|August 19, 2015
Galectin-8 promotes regulatory T-cell differentiation by modulating IL-2 and TGFβ signalingJames F Sampson, Amol Suryawanshi, Wei-Sheng Chen, et al.
Experimental Eye Research|June 20, 2018
Collagen VII deficient mice show morphologic and histologic corneal changes that phenotypically mimic human dystrophic epidermolysis bullosa of the eyeVicki M Chen, Rajani Shelke, Alexander Nyström, et al.
Plos One|July 1, 2015
Galectin-8 Ameliorates Murine Autoimmune Ocular Pathology and Promotes a Regulatory T Cell ResponseJames F Sampson, Eiichi Hasegawa, Lama Mulki, et al.
Plos One|May 2, 2025
CD38-targeted attenuated interferon alpha immunocytokine activates both innate and adaptive immune cells to drive anti-tumor activityJames F Sampson, Hong Zhang, Dongmei Zhang, et al.
Molecular Cancer Therapeutics|October 11, 2019
Synergy between EphA2-ILs-DTXp, a Novel EphA2-Targeted Nanoliposomal Taxane, and PD-1 Inhibitors in Preclinical Tumor ModelsWalid S Kamoun, Anne-Sophie Dugast, James J Suchy, et al.
Science Translational Medicine|October 4, 2019
Antibody-mediated targeting of TNFR2 activates CD8<sup>+</sup> T cells in mice and promotes antitumor immunityEric M Tam, Ross B Fulton, James F Sampson, et al.
Pageof 1